Az emlőrák diagnózisa morfológiai alapú. A daganat mérete, a nyirokcsomóstátus és a hisztológiai grade olyan patológai paraméterek, amelyek a klinikai gyakorlatban jól használhatók a terápia tervezésében. Az ösztrogénreceptor-, a progeszteronreceptor- és a HER2-státust is rutinszerűen meghatározzák ma már a patológiai laboratóriumokban, hogy a betegek ellátásához szükséges prognosztikai és prediktív faktorokról további információt nyújtsanak. Az újabb molekuláris technikákat, így a génexpressziós profil meghatározását kiterjedten használják az emlőrák tanulmányozására, és ezeknek a tudományos erőfeszítéseknek köszönhetően már a klinikai gyakorlatban is elérhetővé váltak molekuláris prognosztikus tesztek. A szerzők áttekintést nyújtanak az invazív emlőrák tradicionális patológiai diagnosztikájáról és molekuláris klasszifikációjáról, elsősorban azok prognosztikai jelentőségére összpontosítva. Orv. Hetil., 2012, 153, 22–30.
Blamey, R. W.: The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast, 1996, 5, 156–157.
Blamey R. W. , 'The design and clinical use of the Nottingham Prognostic Index in breast cancer ' (1996 ) 5 Breast : 156 -157 .
Eifel, P., Axelson, J. A., Costa, J., et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl. Cancer Inst., 2001, 93, 979–989.
Costa J. , 'National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000 ' (2001 ) 93 J. Natl. Cancer Inst. : 979 -989 .
Goldhirsch, A., Ingle, J. N., Gelber, R. D., et al.: Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol., 2009, 20, 1319–1329.
Gelber R. D. , 'Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 ' (2009 ) 20 Ann. Oncol. : 1319 -1329 .
Adjuvant! Online. http://www.adjuvantonline.com/index.jsp (megtekintve: 2011. szeptember 17.)
Lester, S. C., Bose, S., Chen, Y. Y., et al.: Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch. Pathol. Lab. Med., 2009, 133, 1515–1538.
Chen Y. Y. , 'Protocol for the examination of specimens from patients with invasive carcinoma of the breast ' (2009 ) 133 Arch. Pathol. Lab. Med. : 1515 -1538 .
Association of Directors of Anatomic and Surgical Pathology. Checklists and Guidelines. http://www.adasp.org/Checklists/checklists.htm (megtekintve: 2011. szeptember 17.)
Tóth, J., Cserni, G., Kálmán, E., et al.: Az emlőrák patológiai feldolgozása és leletezése. Magy. Onkol., 2000, 44, 14–16.
Kálmán E. , 'Az emlőrák patológiai feldolgozása és leletezése ' (2000 ) 44 Magy. Onkol. : 14 -16 .
Cserni, G., Francz, M., Járay, B., et al.: Pathologic diagnosis and histopathology record of breast cancer. [Az emlőrák patológiai diagnosztikája, feldolgozása és kórszövettani leletezése.] Magy. Onkol., 2010, 54, 217–226. [Hungarian]
Járay B. , 'Pathologic diagnosis and histopathology record of breast cancer. [Az emlőrák patológiai diagnosztikája, feldolgozása és kórszövettani leletezése.] ' (2010 ) 54 Magy. Onkol. : 217 -226 .
Fisher, E. R., Anderson, S., Redmond, C., et al.: Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. 10 year pathologic and clinical discriminants. Cancer, 1993, 71, 2507–2514.
Redmond C. , 'Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. 10 year pathologic and clinical discriminants ' (1993 ) 71 Cancer : 2507 -2514 .
Carter, C. L., Allen, C., Henson, D. E.: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 1989, 63, 181–187.
Henson D. E. , 'Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases ' (1989 ) 63 Cancer : 181 -187 .
Lee, A. H. S., Ellis, I. O.: The Nottingham Prognostic Index for invasive carcinoma of the breast. Pathol. Oncol. Res., 2008, 14, 113–115.
Ellis I. O. , 'The Nottingham Prognostic Index for invasive carcinoma of the breast ' (2008 ) 14 Pathol. Oncol. Res. : 113 -115 .
Elston, C. W., Ellis, I. O.: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991, 19, 403–410.
Ellis I. O. , 'Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up ' (1991 ) 19 Histopathology : 403 -410 .
Blamey, R. W., Ellis, I. O., Pinder, S. E., et al.: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur. J. Cancer, 2007, 43, 1548–1555.
Pinder S. E. , 'Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999 ' (2007 ) 43 Eur. J. Cancer : 1548 -1555 .
Frkovic-Grazio, S., Bracko, M.: Long term prognostic value of Nottingham prognostic histological grade and its components in early (pT1N0M0) breast carcinoma. J. Clin. Pathol., 2002, 55, 88–92.
Bracko M. , 'Long term prognostic value of Nottingham prognostic histological grade and its components in early (pT1N0M0) breast carcinoma ' (2002 ) 55 J. Clin. Pathol. : 88 -92 .
Volpi, A., Bacci, F., Paradiso, A., et al.: Prognostic relevance of histological grade and its components in node negative cancer patients. Mod. Pathol., 2004, 17, 1038–1044.
Paradiso A. , 'Prognostic relevance of histological grade and its components in node negative cancer patients ' (2004 ) 17 Mod. Pathol. : 1038 -1044 .
Boiesen, P., Bendahl, P. O., Anagnostaki, L., et al.: Histologic grading in breast cancer: reproducibility between seven pathologic departments. Acta Oncol., 2000, 39, 41–45.
Anagnostaki L. , 'Histologic grading in breast cancer: reproducibility between seven pathologic departments ' (2000 ) 39 Acta Oncol. : 41 -45 .
Rakha, E. A., Reis-Filho, J. S., Baehner, F., et al.: Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res., 2010, 12, 207–219.
Baehner F. , 'Breast cancer prognostic classification in the molecular era: the role of histological grade ' (2010 ) 12 Breast Cancer Res. : 207 -219 .
Bland, K. I., Menck, H. R., Scott-Conner, C. E., et al.: The National Cancer Center Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer, 1998, 83, 1262–1273.
Scott-Conner C. E. , 'The National Cancer Center Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States ' (1998 ) 83 Cancer : 1262 -1273 .
Fitzgibbons, P. L., Page, D. L., Weaver, D., et al.: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med., 2000, 124, 966–978.
Weaver D. , 'Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 ' (2000 ) 124 Arch. Pathol. Lab. Med. : 966 -978 .
Sahoo, S., Lester, S. C.: Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch. Pathol. Lab. Med., 2009, 133, 633–642.
Lester S. C. , 'Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting ' (2009 ) 133 Arch. Pathol. Lab. Med. : 633 -642 .
Allred, D. C.: Issues and updates: evaluating estrogen receptor-alfa, progesterone receptor, and HER2 in breast cancer. Mod. Pathol., 2010, 23, S52–S59.
Allred D. C. , 'Issues and updates: evaluating estrogen receptor-alfa, progesterone receptor, and HER2 in breast cancer ' (2010 ) 23 Mod. Pathol. : S52 -S59 .
Colleoni, M., Viale, G., Zahrieh, D.: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res., 2004, 10, 6622–6628.
Zahrieh D. , 'Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment ' (2004 ) 10 Clin. Cancer Res. : 6622 -6628 .
Cserni, G., Francz, M., Kálmán, E., et al.: Estrogen receptor negative and progesterone receptor positive breast carcinomas – how frequent are they? Pathol. Oncol. Res., 2011, 17, 663–668.
Kálmán E. , 'Estrogen receptor negative and progesterone receptor positive breast carcinomas – how frequent are they? ' (2011 ) 17 Pathol. Oncol. Res. : 663 -668 .
Bardou, V. J., Arpino, G., Elledge, R. M., et al.: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol., 2003, 21, 1973–1979.
Elledge R. M. , 'Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases ' (2003 ) 21 J. Clin. Oncol. : 1973 -1979 .
Hammond, E. M. H., Allred, D. C., Dowsett, M., et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer. Arch. Pathol. Lab. Med., 2010, 134, 907–922.
Dowsett M. , 'American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer ' (2010 ) 134 Arch. Pathol. Lab. Med. : 907 -922 .
Wolff, A. C., Hammond, E. H., Schwartz, J. N., et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol., 2007, 25, 118–145.
Schwartz J. N. , 'American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer ' (2007 ) 25 J. Clin. Oncol. : 118 -145 .
Schnitt, J.: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod. Pathol., 2010, 23, S60–S64.
Schnitt J. , 'Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy ' (2010 ) 23 Mod. Pathol. : S60 -S64 .
Leong, A. S., Zhunag, Z.: The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology, 2011, 78, 99–114.
Zhunag Z. , 'The changing role of pathology in breast cancer diagnosis and treatment ' (2011 ) 78 Pathobiology : 99 -114 .
Gruver, A. M., Portier, B. P., Tubbs, R. R.: Molecular pathology of breast cancer. The journey from traditional practice toward embracing the complexity of a molecular classification. Arch. Pathol. Lab. Med., 2011, 135, 544–557.
Tubbs R. R. , 'Molecular pathology of breast cancer. The journey from traditional practice toward embracing the complexity of a molecular classification ' (2011 ) 135 Arch. Pathol. Lab. Med. : 544 -557 .
Correa Geyer, F., Reis-Filho, J. S.: Microarray-based gene expression profiling as clinical tool for breast cancer management: are we there yet? Int. J. Surg. Pathol., 2009, 17, 285–302.
Reis-Filho J. S. , 'Microarray-based gene expression profiling as clinical tool for breast cancer management: are we there yet? ' (2009 ) 17 Int. J. Surg. Pathol. : 285 -302 .
Sotiriou, C., Pusztai, L.: Gene-expression signatures in breast cancer. N. Engl. J. Med., 2009, 360, 790–800.
Pusztai L. , 'Gene-expression signatures in breast cancer ' (2009 ) 360 N. Engl. J. Med. : 790 -800 .
Sorlie, T., Perou, C. M., Tibshirani, R., et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 10869–10874.
Tibshirani R. , 'Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications ' (2001 ) 98 Proc. Natl. Acad. Sci. U. S. A. : 10869 -10874 .
Sorlie, T., Tibshirani, R., Parker, J., et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 8418–8423.
Parker J. , 'Repeated observation of breast tumor subtypes in independent gene expression data sets ' (2003 ) 100 Proc. Natl. Acad. Sci. U. S. A. : 8418 -8423 .
Rakha, E., Reis-Filho, J. S.: Basal-like breast carcinoma: from expression profiling to routine practice. Arch. Pathol. Lab. Med., 2009, 133, 860–868.
Reis-Filho J. S. , 'Basal-like breast carcinoma: from expression profiling to routine practice ' (2009 ) 133 Arch. Pathol. Lab. Med. : 860 -868 .
Carey, L. A., Dees, E. C., Sawyer, L., et al.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 2007, 13, 2329–2334.
Sawyer L. , 'The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes ' (2007 ) 13 Clin. Cancer Res. : 2329 -2334 .
Liedtke, C., Mazouni, C., Hess, K. R., et al.: Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J. Clin. Oncol., 2008, 26, 1275–1281.
Hess K. R. , 'Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer ' (2008 ) 26 J. Clin. Oncol. : 1275 -1281 .
Turner, N. C., Reis-Filho, J. S., Russell, A. M., et al.: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 2007, 26, 2126–2132.
Russell A. M. , 'BRCA1 dysfunction in sporadic basal-like breast cancer ' (2007 ) 26 Oncogene : 2126 -2132 .
Cheang, M. C. U., Chia, S. K., Voduc, D., et al.: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst., 2009, 101, 736–750.
Voduc D. , 'Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer ' (2009 ) 101 J. Natl. Cancer Inst. : 736 -750 .
Cheang, M. C., Vodue, D., Bajdik, C.: Basallike breast cancer defined by five biomarkers has superior prognostic value than triple negative phenotype. Clin. Cancer Res., 2008, 14, 1368–1376.
Bajdik C. , 'Basallike breast cancer defined by five biomarkers has superior prognostic value than triple negative phenotype ' (2008 ) 14 Clin. Cancer Res. : 1368 -1376 .
Weigelt, B., Horlings, H. M., Kreike, B., et al.: Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol., 2008, 216, 141–150.
Kreike B. , 'Refinement of breast cancer classification by molecular characterization of histological special types ' (2008 ) 216 J. Pathol. : 141 -150 .
Ivshina, A. V., George, J., Senko, O., et al.: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res., 2006, 66, 10292–10301.
Senko O. , 'Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer ' (2006 ) 66 Cancer Res. : 10292 -10301 .
Sotiriou, C., Wirapati, P., Loi, S., et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98, 262–272.
Loi S. , 'Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis ' (2006 ) 98 J. Natl. Cancer Inst. : 262 -272 .
Sotiriou, C., Piccart, M. J.: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer, 2007, 7, 545–553.
Piccart M. J. , 'Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? ' (2007 ) 7 Nat. Rev. Cancer : 545 -553 .
Wirapati, P., Sotiriou, C., Kunkel, S., et al.: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res., 2008, 10, R65.
Kunkel S. , 'Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures ' (2008 ) 10 Breast Cancer Res. : R65 -.
Paik, S., Shak, S., Tang, G., et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 2004, 351, 2817–2826.
Tang G. , 'A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer ' (2004 ) 351 N. Engl. J. Med. : 2817 -2826 .
Sparano, J. A., Paik, S.: Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol., 2008, 26, 721–728.
Paik S. , 'Development of the 21-gene assay and its application in clinical practice and clinical trials ' (2008 ) 26 J. Clin. Oncol. : 721 -728 .
Van de Vijver, M. J., He, Y. D., van’t Veer, L. J., et al.: A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347, 1999–2009.
Veer L. J. , 'A gene expression signature as a predictor of survival in breast cancer ' (2002 ) 347 N. Engl. J. Med. : 1999 -2009 .
Buyse, M., Loi, S., van’t Veer, L., et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst., 2006, 98, 1183–1192.
Veer L. , 'Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer ' (2006 ) 98 J. Natl. Cancer Inst. : 1183 -1192 .
Cardoso, F., van’t Veer, L., Rutgers, E., et al.: Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol., 2008, 26, 729–735.
Rutgers E. , 'Clinical application of the 70-gene profile: the MINDACT trial ' (2008 ) 26 J. Clin. Oncol. : 729 -735 .
Flanagan, M. B., Dabbs, D. J., Brufsky, A. M., et al.: Histopathologic variables predict Oncotype DX Recurrence Score. Mod. Pathol., 2008, 21, 1255–1261.
Brufsky A. M. , 'Histopathologic variables predict Oncotype DX Recurrence Score ' (2008 ) 21 Mod. Pathol. : 1255 -1261 .